Literature DB >> 20709796

Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression.

Anniina Raitila1, Heli J Lehtonen, Johanna Arola, Elina Heliövaara, Manuel Ahlsten, Marianthi Georgitsi, Anu Jalanko, Anders Paetau, Lauri A Aaltonen, Auli Karhu.   

Abstract

Mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene have been shown to predispose to pituitary adenoma predisposition, a condition characterized by growth hormone (GH)-secreting pituitary tumors. To study AIP-mediated tumorigenesis, we generated an Aip mouse model. Heterozygous mice developed normally but were prone to pituitary adenomas, in particular to those secreting GH. A complete loss of AIP was detected in these lesions, and full penetrance was reached at the age of 15 months. No excess of any other tumor type was found. Ki-67 analysis indicated that Aip-deficient tumors have higher proliferation rates compared with Aip-proficient tumors, suggesting a more aggressive disease. Similar to human AIP-deficient pituitary adenomas, immunohistochemical studies showed that expression of aryl hydrocarbon receptor nuclear translocator 1 or 2 (ARNT or ARNT2) protein was lost in the mouse tumors, suggesting that mechanisms of AIP-related tumorigenesis involve aberrant ARNT function. The Aip(+/-) mouse appears to be an excellent model for the respective human disease phenotype. This model constitutes a tool to further study AIP-associated pituitary tumorigenesis and may be potentially valuable in efforts to develop therapeutic strategies to treat pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709796      PMCID: PMC2947291          DOI: 10.2353/ajpath.2010.100138

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  A survey of genetic and epigenetic variation affecting human gene expression.

Authors:  Tomi Pastinen; Robert Sladek; Scott Gurd; Alya'a Sammak; Bing Ge; Pierre Lepage; Karine Lavergne; Amelie Villeneuve; Tiffany Gaudin; Helena Brändström; Allon Beck; Andrei Verner; Jade Kingsley; Eef Harmsen; Damian Labuda; Kenneth Morgan; Marie-Claude Vohl; Anna K Naumova; Daniel Sinnett; Thomas J Hudson
Journal:  Physiol Genomics       Date:  2004-01-15       Impact factor: 3.107

2.  A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors.

Authors:  J S Crabtree; P C Scacheri; J M Ward; L Garrett-Beal; M R Emmert-Buck; K A Edgemon; D Lorang; S K Libutti; S C Chandrasekharappa; S J Marx; A M Spiegel; F S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

Review 3.  Combined expression of different hormone genes in single cells of normal rat and mouse pituitary.

Authors:  E Seuntjens; A Hauspie; M Roudbaraki; H Vankelecom; C Denef
Journal:  Arch Physiol Biochem       Date:  2002-04       Impact factor: 4.076

4.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.

Authors:  E Knosp; K Kitz; A Perneczky
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

5.  A hypomorphic allele of aryl hydrocarbon receptor-associated protein-9 produces a phenocopy of the AHR-null mouse.

Authors:  Bernice C Lin; Linh P Nguyen; Jacqueline A Walisser; Christopher A Bradfield
Journal:  Mol Pharmacol       Date:  2008-07-31       Impact factor: 4.436

6.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

7.  The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription.

Authors:  Sara Brunnberg; Katarina Pettersson; Elin Rydin; Jason Matthews; Annika Hanberg; Ingemar Pongratz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-16       Impact factor: 11.205

8.  No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia.

Authors:  A Raitila; M Georgitsi; A Karhu; K Tuppurainen; M J Mäkinen; K Birkenkamp-Demtröder; K Salmenkivi; T F Orntoft; J Arola; V Launonen; P Vahteristo; L A Aaltonen
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

9.  Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality.

Authors:  Bernice C Lin; Ruth Sullivan; Youngsook Lee; Susan Moran; Edward Glover; Christopher A Bradfield
Journal:  J Biol Chem       Date:  2007-10-04       Impact factor: 5.157

10.  Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations.

Authors:  Marianthi Georgitsi; Anniina Raitila; Auli Karhu; Karoliina Tuppurainen; Markus J Mäkinen; Outi Vierimaa; Ralf Paschke; Wolfgang Saeger; Rob B van der Luijt; Timo Sane; Mercedes Robledo; Ernesto De Menis; Robert J Weil; Anna Wasik; Grzegorz Zielinski; Olga Lucewicz; Jan Lubinski; Virpi Launonen; Pia Vahteristo; Lauri A Aaltonen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-28       Impact factor: 11.205

View more
  33 in total

Review 1.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

2.  Signaling network map of the aryl hydrocarbon receptor.

Authors:  Soujanya D Yelamanchi; Hitendra Singh Solanki; Aneesha Radhakrishnan; Lavanya Balakrishnan; Jayshree Advani; Remya Raja; Nandini A Sahasrabuddhe; Premendu Prakash Mathur; Pinaki Dutta; T S Keshava Prasad; Márta Korbonits; Aditi Chatterjee; Harsha Gowda; Kanchan Kumar Mukherjee
Journal:  J Cell Commun Signal       Date:  2016-07-27       Impact factor: 5.782

Review 3.  Familial isolated pituitary adenomas: from genetics to therapy.

Authors:  Federica Guaraldi; Roberto Salvatori
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

4.  Prkar1a haploinsufficiency ameliorates the growth hormone excess phenotype in Aip-deficient mice.

Authors:  Marie Helene Schernthaner-Reiter; Giampaolo Trivellin; Thomas Roetzer; Johannes A Hainfellner; Matthew F Starost; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

5.  A novel C-terminal nonsense mutation, Q315X, of the aryl hydrocarbon receptor-interacting protein gene in a Japanese familial isolated pituitary adenoma family.

Authors:  Takeo Iwata; Shozo Yamada; Junko Ito; Naoko Inoshita; Noriko Mizusawa; Shinji Ono; Katsuhiko Yoshimoto
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

6.  Interaction of AIP with protein kinase A (cAMP-dependent protein kinase).

Authors:  Marie Helene Schernthaner-Reiter; Giampaolo Trivellin; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

7.  Aryl Hydrocarbon Receptor Interacting Protein Targets IRF7 to Suppress Antiviral Signaling and the Induction of Type I Interferon.

Authors:  Qinjie Zhou; Alfonso Lavorgna; Melissa Bowman; John Hiscott; Edward W Harhaj
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

Review 8.  The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas.

Authors:  Catrin Lloyd; Ashley Grossman
Journal:  Endocrine       Date:  2013-12-24       Impact factor: 3.633

Review 9.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

Review 10.  Genetics of gigantism and acromegaly.

Authors:  Fady Hannah-Shmouni; Giampaolo Trivellin; Constantine A Stratakis
Journal:  Growth Horm IGF Res       Date:  2016-08-10       Impact factor: 2.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.